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Open acca b s t r a c t
Exogenous brain-derived neurotrophic factor (BDNF) can regulate behavioral sensitization and condi-
tioned place preference (CPP) when animals are exposed to repeated cocaine administration. However, it
is unclear whether BDNF signaling through the TrkB receptor can mediate these behavioral responses
when animals are given a single cocaine exposure. Because TrkB knockout mice die as neonates, we
engineered a transgenic mouse that expressed a dominant negative form of TrkB (dnTrkB) in a condi-
tional and reversible manner. We assessed also activation of endogenous TrkB by quantifying levels of
phosphorylated TrkB (p-TrkB) in the nucleus accumbens (NAc). We found that a single exposure to
cocaine was sufﬁcient to increase p-TrkB within the NAc 9e12 h after administration. Expression of the
dnTrkB transgene not only prevented the acute cocaine-induced increase in p-TrkB, but it also prevented
behavioral sensitization and CPP following a single cocaine injection. These ﬁndings demonstrate that
TrkB activation is required both for behavioral sensitization and CPP to a single cocaine exposure. The fact
that enhanced TrkB activation is induced within 9 h of a single injection of cocaine suggests that inhi-
bition of TrkB signaling commencing hours after cocaine exposure may prevent at least the initial
antecedents to the sensitizing and reinforcing effects of this psychostimulant.
 2010 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The actions of brain-derived neurotrophic factor (BDNF) are
exerted through the tropomyosin-related tyrosine kinase B (TrkB)
and p75NTR receptors (Kalb, 2005; Reichardt, 2006). Most BDNF-
mediated events related to neural plasticity are conveyed through
the TrkB receptor, while activation of p75 is concerned primarily
with cell survival or apoptosis. Activation of the TrkB receptor has
been implicated in various neuropsychiatric conditions that include
epileptogenesis (He et al., 2004), depression (Berton et al., 2006;
Nibuya et al., 1995; Siuciak et al., 1997), and drug abuse (Butovsky
et al., 2005; Lu et al., 2004; McGough et al., 2004; Graham et al.,
2007, 2009).try and Behavioral Sciences,
0, USA. Tel.: þ 1 (919) 684
tsel).
ess under CC BY-NC-ND license. Over the years, considerable evidence has accrued showing
that cocaine can inﬂuence the levels of BDNF (Pierce and Bari,
2001; Russo et al., 2009). For instance, acute or repeated admin-
istration of cocaine increases the concentrations of BDNF protein
in rat neostriatum and/or nucleus accumbens (NAc) (Berglind
et al., 2007; Filip et al., 2006; Zhang et al., 2002). The elevation
in the NAc appears to be region-speciﬁc since levels of BDNF are
increased in the shell but not in the core (Graham et al., 2007). By
comparison, levels of TrkB receptor protein are enhanced in both
areas (Graham et al., 2009). Withdrawal from cocaine further
potentiates the concentrations of BDNF in the NAc (Grimm et al.,
2003; Pu et al., 2006). Additionally, withdrawal facilitates long-
term potentiation in the ventral tegmental area and this effect
can be blocked with a TrkB receptor scavenger or tyrosine kinase
inhibitor (Pu et al., 2006). Infusion of BDNF into rat NAc is sufﬁ-
cient to augment behavioral sensitization and self-administration
of cocaine (Horger et al., 1999). This enhancement in self-
administration persists for at least one month after the BDNF
infusions have terminated (Grimm et al., 2003; Horger et al., 1999).
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the rat NAc potentiates cocaine-induced behavioral sensitization
and conditioned place preference (CPP), and the infections prolong
CPP extinction and increase CPP reinstatement (Bahi et al., 2008).
By comparison, reductions of BDNF by genetic manipulation or by
siRNA procedures serve to reduce cocaine-responsiveness in the
open ﬁeld and CPP (Graham et al., 2009; Hall et al., 2003; Horger
et al., 1999). Importantly, infusion of BDNF antiserum into the NAc
attenuates cocaine self-administration and decreases relapse
(Graham et al., 2007). From these reports, we have hypothesized
that a single injection of cocaine will enhance TrkB activation
within the NAc and that this response is required for the
appearance of both behavioral sensitization and CPP. To test
these hypotheses, we have engineered a transgenic mouse that
expresses a dominant negative form of TrkB within subpopula-
tions of forebrain CNS neurons in a temporally controlled manner.
We have utilized a behavioral sensitization paradigm that involves
a single exposure to cocaine (see Grignaschi et al., 2004; Kalivas
and Alesdatter, 1993; Vanderschuren et al., 1999) followed by
a challenge injection 28 days later because this procedure permits
an investigation of the initial molecular and cellular mechanisms
that underlie early stages of addictive behaviors that are not
confounded by the additional changes that may occur with
repeated cocaine exposure.
2. Methods
2.1. Generation of transgenic mice
Transgenic mice were generated that express a dominant negative mutation of
the TrkB receptor (accession number X17647; National Center for Biotechnology,
Bethesda, Maryland). Brieﬂy, the 50 portion of TrkB (bases 20e1408) was cloned by
PCR from a mouse brain cDNA library (Clontech, Mountain View, CA) using a forward
primer: 50-GATGATATCCGTTAGAGCCCAGTCGCTGCTTCAGC-30; and reverse primer:
50-GTGATCTGAGGTTGGAGACTCGAG-30 . To render TrkB kinase inactive, GeneEditor kit
(Promega, Madison, WI) was used to modify base pairs 2222e2224 from AAG (Lys) to
GCT (Ala) using the primer 50-CTGGTGGCTGTGGCTACGCTGAAGGAC-30; thereby,
creating plasmid pSP73-dnTrkB (dominant negative TrkB). This construct was excised
and cloned into pMM400 (a kind gift of Dr. Mark Mayford, Scripps Research Institute,
San Diego, CA), placing dnTrkB under control of the tet-operon (tetO) promoter
(Mayford et al., 1996). DNA sequencing conﬁrmed the sequences were correct. The
plasmid was digested, the insert containing the tet-O promoter and dnTrkB construct
was excised, puriﬁed, and microinjected into B6SJLF1/J single-cell embryos (Duke
University Transgenic Facility, Durham, NC). Mice expressing the tetracycline trans-
activator (tTA) gene under control of the CAMKIIa promoter and maintained on
a C57BL/6 background were provided by Dr. Mark Mayford (Mayford et al., 1996).
These mice were crossed to founder dnTrkB mice to generate double-transgenic (dtg)
animals. Mice used in this study were age-matched 3e5 month old males with
littermate controls where minimal numbers of mice were used to reach statistical
signiﬁcance. Standard laboratory chow and water were provided ad libitum. Animals
were housed in a humidity- and temperature-controlled room under a 14:10 h light/
dark cycle (lights on 0700 h). To regulate transgenic expression in vivo, 100 ng/ml
doxycycline hyclate (dox; Sigma, St. Louis, MO) was provided in the drinking water at
least 14 days prior to study. Experiments were conducted in accordance with an
approved protocol from the Duke University Institutional Animal Care and Use
Committee. All investigations were performed to minimize any potential pain or
discomfort to the animals and to utilize alternatives to in vivo experiments.
2.2. Generation of dnTrkB-speciﬁc antibody
Rabbits were immunized with a keyhole limpet hemocyanin-linked dnTrkB-
FLAG antigen (i.e., PVYLDILG-DYKDDDDK) in complete Freund's adjuvant and
boosted with antigen in Freund's incomplete adjuvant 2, 6, and 8 wks later. Serum
was collected 10 wks after the initial injection and total IgG was concentrated using
the ImmunoPure IgG Puriﬁcation Kit (Pierce, Rockford, IL).
2.3. DnTrkB immunohistochemistry
Brain sections were prepared as described (Danzer et al., 2002). To reduce cross-
reactivity, the dnTrkB primary antibody (1:1000 dilution) was pre-absorbed with
1 mg wild type (WT) brain homogenate per ml antibody, slides were washed,
incubated with horseradish peroxidase (HRP) conjugated goat anti-rabbit antibody
(1:1000 dilution; Jackson Immunoresearch, West Grove, PA), and rinsed. Color was
developed using the SigmaFast diaminobenzadine reaction (Sigma).2.4. Western blot
Mice were euthanized and heads immediately immersed in liquid nitrogen to
cool but not freeze the brain. The brainwas removed and cortex, hippocampus, NAc,
dorsal striatum, brainstem, and/or cerebellum were dissected. Tissues were
homogenized in ice-cold lysis buffer [20 mM Tris (pH 7.4), 137 mM NaCl, 1% Igepal,
10% glycerol, 1 mM PMSF, and 1.5 mM sodium orthovanadate with Complete
Protease Inhibitor (Roche, Indianapolis, IN)], mixed 30 min at 4 C, and cleared by
centrifugation at 16,000 g at 4 C for 10 min. Homogenates were diluted in SDS
sample buffer and boiled. Homogenates (15 mg) were resolved by SDS-PAGE and
electrophoretically transferred to Immobilon-P membranes (Millipore, Billerica,
MA). Blots were blocked with 3% non-fat dry milk and 0.05% Tween-20 in TBS
(25 mM Tris base, 136 mM NaCl, 2.7 mM KCl, pH¼ 7.4). The top half of each blot was
incubated with anti-dnTrkB pre-absorbed antibody (1:2500 dilution). To control for
loading and transfer, the bottom blot was incubated with anti-b-actin antibody
(1:10,000 dilution; Sigma). Blots were washed, incubated with secondary antibody
[1:2000 dilution HRP-conjugated goat anti-rabbit IgG (Jackson Immunoresearch) for
anti-dnTrkB and 1:5000 dilution HRP-conjugated donkey anti-mouse IgG (Chem-
icon, Temecula, CA) for b-actin antisera]. Blots were washed, incubated with
SuperSignalWest Pico Chemiluminescent Substrate (Pierce), and exposed to Biomax
MR ﬁlm (Kodak, Rochester, NY). Band intensity was quantiﬁed using ImageQuant
software (Molecular Dynamics, Sunnyvale, CA).
2.5. Immunoprecipitation
Naïve mice were treated with saline or 20 mg/kg cocaine (i.p.). At various times
after injection, mice were anesthetized with pentobarbital and decapitated. Heads
were placed into liquid nitrogen to cool, but not freeze, the brain. A coronal section
(approximately 0.95e1.95 mm bregma) was taken. The NAc was dissected from this
section, homogenized in ice-cold lysis buffer, and homogenates were pooled from 2
mice in each group. The sample was diluted to 1 mg/ml in lysis buffer. For immu-
noprecipitation, 3 mg anti-phosphotyrosine antibody (p-Tyr clone 4G10; Upstate,
Waltham, MA) and 60 ml protein G agarose (Roche) were added, and mixed for 1 h at
4 C. Tubes were centrifuged at 16,000 g for 2 min at 4 C, and the pellets were
washed 3 in lysis buffer, re-suspended in sample buffer [63 mM TriseHCl (pH 6.8),
75 mM dithiothreitol, 2% SDS, 7.5% glycerol, 0.005% bromophenol blue] and boiled.
Western blot was performed as described above using the anti-TrkB antibody
(1:1000 dilution; Upstate) and HRP-labeled goat anti-mouse IgG1 secondary anti-
body (1:1000 dilution; Jackson Immunoresearch).
2.6. PC12 cell assay
PC12 cells stably expressing TrkB (a kind gift of Dr. Moses Chao, New York
UniversityMedical Center, NewYork, NY)were transfectedwith gold particles coated
with one of the following plasmid combinations: 0.25 mg GFP (pEGFP-IRESneo;
a generous gift of Dr. Nancy Ip, Hong Kong University of Science and Technology,
Hong Kong, China)þ 1.75 mg pcDNA3/mg gold or 0.25 mg GFPþ 1.75 mg dnTrkB/mg
gold (seeDanzer et al., 2002). Immediately after transfection, vehicle, 50 ng/mLBDNF
(Sigma), or 50 ng/mL neurotrophic growth factor (NGF; Sigma) was added to
mediumþ serum. Three days later, cells were ﬁxed in 4% paraformaldehyde in PBS,
washed with methanol, and rinsed with PBS. Cells were blocked with PBSþ 3% BSA,
10% normal goat serum, and 0.5% Triton-X100. Slides were incubated with mouse
anti-FLAG primary antibody (1:1000 dilution; Sigma), followed by secondary anti-
body (1:1000 dilution, Alexa Fluor 594 goat anti-mouse IgG; Invitrogen). Cells were
visualized under a ﬂuorescent microscope. A GFP-ﬂuorescent cell was deﬁned as
“differentiated” if it extended two ormore neurites, each longer than twice thewidth
of the cell body. To ensure detection of dnTrkB expression in transfected cells, only
those cells containing both GFP ﬂuorescence and FLAG immunoreactivities were
counted. For cells transfected with GFPþ pcDNA3, no cells exhibited FLAG immu-
noreactivity and all ﬂuorescent cells were counted.
2.7. Neurophysiological status
General neurophysiological status was assessed as described (Rodriguiz et al.,
2008) by an observer blinded to genotype.
2.8. Morris water maze
This test was conducted as described (Rodriguiz and Wetsel, 2006; Rodriguiz
et al., 2008). Total swim distance, latency to locate the platform, and swim
velocity were calculated from Ethovision (Noldus Information Technology, Leesburg,
VA, USA).
2.9. Locomotor activity
Mice were evaluated in the open ﬁeld (see Pogorelov et al., 2005). Locomotor
(distance traveled) and stereotypical activities (repeated beam-breaks <1 s) were
monitored (AccuScan Instruments, Columbus, OH). Naïve mice were habituated to
the open ﬁeld for 60 min, injected (i.p.) with saline or cocaine (Sigma), and
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to their home cages where they remained for 28 days. At the end of this time, all
mice were challenged with a single injection of 20 mg/kg cocaine (i.p.) as described
above.
2.10. CPP
Training and testing were conducted in a mouse CPP apparatus consisting of
black and white chambers (16.8 12.712.7 cm), separated by manually-operated
doors connected to a gray compartment (7.212.712.7 cm) (Med Associates,
St. Albans, VT). Testing took place over 8 days. Mice were allowed to explore the
apparatus for 30 min over 4 consecutive days. On day 5, mice were randomly given
saline or cocaine and conﬁned to either the black or white chamber for 30 min. On
day 6, mice that were given cocaine on day 5 received saline and vice versa; each
mouse was conﬁned to the chamber opposite that on day 5. On day 8 mice were
permitted free access to the entire apparatus for 30 min. The data are presented as
the time spent in the saline- and cocaine-paired chambers; the percent increase in
time spent in the cocaine-paired chamber from pre-training to testing, and as
preference scores represented as the time spent in the saline chamber subtracted
from the time spent in the cocaine chamber divided by the total time spent in both
chambers.
2.11. Statistical analyses
The data are expressed as means SEM. All analyses were conducted with the
Statistical Package for the Social Sciences, Version 11.0 (Chicago, IL). PC12 cell
differentiation was evaluated by chi-square analysis. Results from all biochemical
experiments with mice represent data from individual animals from experiments.
Western blot band intensities were evaluated by Student's t-test or ANOVA. For the
cocaine dose-response study in the open ﬁeld, behavioral sensitization, and CPP
experiments, the data were analyzed by repeated measures ANOVA (RMANOVA).Fig. 1. Western blot analysis of total TrkB and p-Trk-B. (A) Western blot of immunoprec
euthanized 10 min to 24 h later. Cocaine exposure induces an increase in p-TrkB immunorea
p-TrkB immunoreactivity 9 and 12 h after injection [F1,35¼ 5.46, p< 0.024]. N¼ 3 experime
euthanized 10 min to 24 h following saline (S) or cocaine (C) administration; b-actin was used
over time. N¼ 3 experiments.These data were also analyzed by ANOVA where locomotor activity in ﬁrst 20 min
following injection was summed for each genotype and dose and for the CPP results
expressed as the percent change in time spent in the cocaine-paired chamber from
pre-training to test and as preference scores. Post-hoc analyses were by Bonferroni
corrected pair-wise comparisons. Signiﬁcance was set at p< 0.05.3. Results
3.1. Cocaine exposure increases p-TrkB contents in the NAc
Previous reports implicating a role for BDNF/TrkB signaling in
animal models of drug abuse (Bahi et al., 2008; Graham et al., 2007,
2009; Grimm et al., 2003; Hall et al., 2003; Horger et al., 1999) raise
the possibility that drug exposure may increase TrkB activation
within the NAc. To test this idea, we examined the phosphorylation
status of TrkB, a surrogate measure of TrkB activation, in WT mice
euthanized at various times after a single injection of saline or
20 mg/kg cocaine (i.p.). Levels of p-TrkB in the NAc were analyzed
by immunoprecipitationwith a p-Tyr antibody andWestern blot for
TrkB. Compared to saline, cocaine treatment induced a transient
increase in p-TrkB that wasmaximal 9e12 h after injection, and this
effect was largely reversed within 24 h (Fig. 1A). Quantitative
analysis of p-TrkB immunoreactivity 9 h after injection demon-
strated that cocaine signiﬁcantly increased p-TrkB levels compared
to saline (Fig. 1B). By contrast, Western blot for total TrkB revealed
immunoreactivities for the saline and cocaine-treated groups to beipitable p-Trk-B from NAc homogenates from WT mice given saline or cocaine and
ctivity in the NAc that is maximal 9 h after injection. (B) Cocaine signiﬁcantly increased
nts. (C) Western blot analysis of total TrkB expression in NAc homogenates from mice
as a loading control. (D) Densitometric analysis of total TrkB/b-actin immunoreactivity
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demonstrate that a single exposure to cocaine induces a selective
but transient increase in p-TrkB within the NAc.
3.2. Mutant TrkB selectively inhibits TrkB signaling in PC12 cells
Our initial ﬁnding demonstrated that a single exposure to
a moderate dose of cocaine is sufﬁcient to increase p-TrkB levels in
the NAc. To examine the functional signiﬁcance of this event, we
engineered a mutant mouse in which TrkB activation could be
selectively inhibited in adulthood. To this purpose, we introduced
a single amino-acid substitution (K571A) into the TrkB receptor
cDNA, a mutation that renders the protein-kinase inactive. To
determine whether this construct (dnTrkB) would exert dominant
inhibitory action on endogenous TrkB signaling, we examined its
effects on TrkB-mediated responses in a pheochromocytoma (PC12)
cell line. These cells stably express endogenous TrkB in addition to
endogenous TrkA receptors and elaborate neurites in response to
BDNF or NGF treatments (Fig. 2A). Proliferating PC12 cells were
transfected with plasmids containing either GFPþ pcDNA con-
taining the empty vector or GFPþ pcDNA containing the dnTrkB.
Cells were treated with vehicle, NGF, or BDNF for three days. At the
end of this time, expression of dnTrkB was detected by immuno-
cytoreactivity of its FLAG epitope tag, and neurite outgrowth was
examined by GFP immunocytochemistry. Vehicle alone induced no
differentiation (Fig. 2A, Left; Fig. 2B, Left). As expected, both NGFFig. 2. DnTrkB selectively abolishes response to BDNF in PC12 cells. (A) PC12 cells
stably expressing TrkB lack neurites in the absence of neurotrophin treatment (far left
panel), but differentiate in response to NGF (middle panel) or BDNF (right panel).
(B) PC12 cells endogenously expressing the TrkB receptor were transfected with
GFPþ pcDNA3 (empty vector; open bars) or GFPþ dnTrkB (gray bars) plasmids and
were treated with vehicle, 50 ng/mL NGF, or 50 ng/mL BDNF for 3 days. Expression of
dnTrkB exerted no effect on the response to vehicle or NGF (empty vector, 30.0%
differentiation; dnTrkB, 35.7% differentiation; c2¼ 0.188, n.s.), but it eliminated the
BDNF response (empty vector, 32% differentiation; dnTrkB, w0% differentiation;
c2¼ 5.803, p< 0.05). N¼ 2 experiments.and BDNF induced striking differentiation to equivalent extents in
cells transfected with the empty vector (Fig. 2A, Middle and Right;
Fig. 2B, Middle and Right, pcDNA3-mediated responses to NGF and
BDNF). Expression of dnTrkB selectively eliminated BDNF-induced
differentiation (Fig. 2B, Right, dnTrkB-mediated response), but
had no effect on NGF-induced differentiation (Fig. 2B, Middle,
dnTrkB-mediated response). These results demonstrate the efﬁcacy
and selectivity of dnTrkB inhibition of wild type TrkB.
3.3. Transgenic mice express dnTrkB in a region-speciﬁc
and doxycycline-regulated manner
To selectively inhibit TrkB activation in forebrain, we engineered
mice in which expression of dnTrkB was controlled by the tet-off
system (Gossen and Bujard, 1992). In this system, expression of
the dnTrkB transgene was placed under the control of the tetO
promoter, which contained a minimal cytomeglovirus promoter
that alonewas insufﬁcient to cause transcription. Transcriptionwas
activated when the product of the second transgene, the tetracy-
cline transactivator (tTA), bound to the tetO promoter and was
inhibited when a tetracycline was administered to the animal.
We ﬁrst developed 10 different lines of dnTrkB transgenic mice.
Animals from each of these lines were crossed with mice that
express tTA under the control of the CAMKIIa promoter (Mayford
line B mice; Mayford et al., 1996) to generate bitransgenic (double-
transgenic or “dtg”) mice that express dnTrkB in a tetracycline-
regulated manner. The CAMKIIa promoter restricts expression of
tTA and, therefore, of dnTrkB to postmitotic neurons that express
CAMKIIa in the forebrain (Burgin et al.,1990;Hanson and Schulman,
1992; Miller and Kennedy, 1986). Immunohistochemical analyses
using an antibody speciﬁc to the dnTrkB protein revealed that
dnTrkB expression was restricted to the forebrain in dtg mice with
no detectable dnTrkB immunoreactivity inWTanimals (Fig. 3AeD).
Within dtg forebrain, the highest expression of dnTrkB was found
throughout the striatum with lower levels in cortex and hippo-
campus (Fig. 3BeD). The dnTrkB immunoreactivity was absent in
dtg midbrain, including the ventral tegmental area (data not
shown). These results were conﬁrmed by Western blot analyses of
the dissected brain regions (Fig. 3E). The line of mice (line 7) with
the highest level of expression was used in this study.
In the tet-off system, expression of the transgene is prevented by
dox, a tetracycline derivative which inhibits the tTA-tetO interaction.
To test dox-responsiveness in our animals, adult WT and dtg mice
raised in the absence of dox were provided 100 ng/ml dox in their
drinking water and dnTrkB expression in striatumwas examined by
Western blot. Expression of dnTrkB was reduced after 7 days of
treatment and was completely eliminated at 14 days (Fig. 3F). When
doxwaswithdrawn subsequently, dnTrkB expressionwas restored to
basal levels within 14 days. Taken together, these ﬁndings show that
the dnTrkB transgene is expressed selectively in the forebrain and its
expression can be regulated by dox treatment.
3.4. Transgenic mice appear behaviorally normal
Allmicedescribed in thisexperimentwere raised in theabsenceof
dox, which permits expression of dnTrkB in the forebrain beginning
between E15 and P0 as determined by expression in this line of
CaMKIIa-tTA mice (Krestel et al., 2001; Yamamoto et al., 2000). In
previous studies, reduced expression of the TrkB receptor beginning
in embryonic development resulted in behavioral disorders and
physical impairments including runting, obesity, motor neuron deﬁ-
ciencies, and, in some instances, increased mortality (He et al., 2004;
Klein et al., 1993; Luikart et al., 2005; Xu et al., 2003). We were con-
cerned that inhibition of TrkB signaling mediated by dnTrkB expres-
sion could produce a similar phenotype. For this purpose,
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mice raised in the absence of dox. No overt differences between WT
and dtg animals were detected in general appearance, body weight,
postural and righting reﬂexes, balance, coordination, strength, or in
the elevated zero maze or forced swim tests (Supplementary Table
S1). Likewise, no differences between WT and mutant mice were
found in the Morris water maze (Supplementary Fig. S1). Together,
these data demonstrate that expression of dnTrkB in a subset of
principal neurons in forebrain beginning in late embryonic life and
persisting into adulthood results in no detectable general behavioral
impairments.
3.5. The dnTrkB transgenic mice respond normally
to cocaine in the open ﬁeld
Previous studies have indicated that TrkB signaling may play
a role in locomotor activity after acute cocaine administration
(Horger et al., 1999). As an initial screen for potential alterations in
response to acute cocaine exposure, locomotor activity was exam-
ined inWT and dtg mice that had not been treated with dox. In this
experiment,micewere habituated to the open ﬁeld for 1 h. Separate
naïve groups of animals were given saline or 10, 15, or 20 mg/kg
cocaine (i.p.) and immediately returned to the open ﬁeld for an
additional 2 h. Importantly, pre-injection locomotor activitywas not
different between the genotypes, and WT and dtg mice showed
increased activity in a dose-dependent manner to acute cocaine
injection (Fig. 4AeD). Administration of 15 or 20 mg/kg, but not 0 or
10 mg/kg, resulted in an immediate increase in locomotion in both
genotypes and this activity returned to baselinewithin 2 h. Tomore
readily compare locomotor activities across genotypes and cocaine
doses, activity was collapsed over the ﬁrst 20 min following injec-
tion (Fig. 4B,D). Overall, increasing the acute cocaine dose resulted in
similar increases in locomotor activity in both WT and dtg mice.
3.6. Expression of dnTrkB prevents acute cocaine sensitization
Repeated administration of cocaine induces behavioral sensiti-
zation and this response is thought to be due to alterations in
neuronal plasticity that occur over the course of multiple exposures
to the psychostimulant (Robinson and Berridge, 2001). However,
sensitization can also occur following a single injection of cocaine
(Grignaschi et al., 2004; Kalivas and Alesdatter, 1993;
Vanderschuren et al., 1999). Although TrkB activation has been
implicated in diverse neuronal plasticities (Black and Lessmann,
1999; Bramham and Messaoudi, 2005; Lessmann, 1998), it is
unclear whether TrkB signaling is required for behavioral sensiti-
zation to a single injection of cocaine. To test this possibility and
because p-TrkB immunoreactivity was evident 9e12 h after cocaine
administration, the single injection procedure for behavioralFig. 3. DnTrkB is expressed throughout the forebrain of dtg mice and is regulated by
doxycycline (dox). (AeD) Horizontal sections of dtg (left panels) and WT (right panels)
brain that were processed for anti-dnTrkB immunoreactivity demonstrate expression
of dnTrkB throughout the forebrain only in dtg mice. Expression is highest in striatum
(Str) and nucleus accumbens (NAc) (B), with lower levels in cortex (Ctx) (C) and
hippocampus (Hip) (D). N¼ 2 experiments. (E) Western blot of homogenates from
various brain regions of dnTrkB mice shows relative levels of dnTrkB expression in Str
(lane 1), Ctx (lane 2) olfactory bulb (Olf; lane 3), Hip (lane 4), and amygdala/piriform
cortex (A/PC; lane 5). As expected, expression is absent in cerebellum (CB; lane 6) and
brainstem (BS; lane 7) of dtg mice and is absent from Str of WT mice (lane 8). N¼ 3
experiments. (F) Dox administration for 7 days exerts no effect on dnTrkB expression in
Str from WT mice (lane 1) because the transgene is not expressed in these animals.
However, in dnTrkB mice dox treatment for 7 days reduces dnTrkB expression (lane 3)
and after 14 days of treatment, dnTrkB is no longer detectable (lane 4). Expression of
the dnTrkB transgene is restored following removal of dox from the drinking water for
14 days (lane 5). N¼ 3 experiments.
Fig. 4. Locomotor activity after acute cocaine treatment. Mice were habituated to the open ﬁeld for 1 h, given saline or cocaine (i.p.), and immediately returned to the open ﬁeld for
2 h. Effects of saline, 10, 15, or 20 mg/kg cocaine on open ﬁeld activity in WT (A,B) or dtg (C,D) mice. Both WT (A) and dtg (C) mice display dose-dependent increases in locomotor
activity following administration of cocaine. RMANOVA for distance traveled for the ﬁrst h before drug injection was not signiﬁcant. RMANOVA over the 2 h post-injection period
revealed signiﬁcant main effects of time [F23,851¼47.528, p< 0.001] and a signiﬁcant time by treatment interaction [F69,851¼10.612, p< 0.001]. No signiﬁcant time by genotype or
time by genotype by treatment interactions were discerned. Bonferroni corrected pair-wise comparisons for the time by treatment effects revealed that WT and dtg mice had
enhanced locomotor responses to 10, 15, and 20 mg/kg cocaine at 5, 10, 15, and 20 min post-injection (ps< 0.04) relative to the vehicle controls. Cumulative total distance traveled
during 20 min before and following drug injection is presented for WT (B) and dtg (D) mice. RMANOVA for distance traveled 20 min pre- and post-injection revealed signiﬁcant
effects of time [F1,37¼ 91.633, p< 0.001] and a signiﬁcant time by dose interaction [F3,37¼ 35.421, p< 0.001]. No effects of genotype were observed. Bonferroni corrected pair-wise
comparisons conﬁrmed that WT and dtg animals did not differ in locomotor activities prior to or following cocaine administration. Behavioral responses to both 15 and 20 mg/kg
cocaine were augmented relative to animals given vehicle (ps< 0.02) or 10 mg/kg cocaine (ps< 0.04). At 0 mg/kg cocaine: N¼ 12 WT and 4 dtg mice, 10 mg/kg cocaine: N¼ 4 WT
and 4 dtg mice, 15 mg/kg cocaine: N¼ 4 WT and 5 dtg mice, 20 mg/kg cocaine: N¼ 5 WT and 7 dtg mice were tested; þp< 0.05, within genotype from vehicle.
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of the experiment, WT and dtg mice (raised in the absence of dox)
were placed into the open ﬁeld for 1 h to habituate them to the
novel environment. Animals were given vehicle or 20 mg/kg
cocaine (i.p.) and immediately returned to the open ﬁeld for 2 h.
When cumulative locomotor activity was examined during
the 20 min period before drug administration and compared to
the 20 min immediately after injection, cocaine was found to
produce a robust increase in locomotion for both WT and dtg mice
(Fig. 5A, B). Importantly, the increase in locomotion after cocaine
administration was similar for WT and dtg mice. Four weeks later,
all animals were challenged with a single injection of 20 mg/kg
cocaine (Fig. 5A, B). WT mice showed marked sensitization to the
locomotor-stimulating effects of the single previous administration
of cocaine, whereas dtg mice gave no evidence of sensitization as
the magnitude of locomotion to cocaine stimulation on day 28
was less than that at the time of the ﬁrst cocaine exposure.
These ﬁndings demonstrate that expression of dnTrkB prevents
behavioral sensitization to a single injection of cocaine.As dnTrkB is expressed beginning in late embryonic develop-
ment and persists throughout adulthood, the absence of behavioral
sensitization to acute cocaine administration led us to question
whether the failure of dtg mice to show sensitizationwas a result of
inhibition of TrkB activation by the dnTrkB transgene at the time of
the experiment or was a result of developmental impairment from
early and lifelong dnTrkB expression. To address this question, we
selectively inhibited dnTrkB expression in adulthood by providing
dox in the drinking water. Accordingly, WT and dtg mice were
raised in the absence of dox and were ﬁrst placed on dox as adults
beginning 14 days prior to the ﬁrst cocaine exposure. Dox exerted
no effect on WT responses to cocaine either during the acute
or challenge phases of the experiment because these animals
exhibited robust cocaine sensitization (Fig. 5A, Supplementary
Fig. S2). Interestingly, suppression of expression of the dnTrkB
transgene in adult dtg mice alleviated the blockade of behavioral
sensitization in these mutants because sensitization to a single
cocaine injection was readily apparent in the dox-treated dtg
mice (Fig. 5B, Supplementary Fig. S2). Together with the ﬁndings
Fig. 5. Expression of the dnTrkB transgene prevents sensitization to a single injection of cocaine. Mice were tested as described in Fig. 4. The data are displayed as activity 20 min
just prior to and immediately after drug injection. (A) WT mice treated without (open bars) or with dox (hatched bars) have similar low levels of locomotion at baseline. Activity is
increased upon ﬁrst exposure to 20 mg/kg cocaine (acute) and is further augmented when challenged with the same dose 28 days later (challenge). (B) Relative to baseline, dtg mice
treated without dox (ﬁlled bars) display similar increases in locomotor activity in response to the ﬁrst injection of cocaine as WT mice, but activity is not further enhanced at
challenge 28 days later. Dox treatment of dtg mice (ﬁlled-hatched bars) rescues the behavioral response at 28 days. RMANOVA revealed signiﬁcant main effects of condition
(baseline, acute, challenge) [F2,84¼121.877, p< 0.001] and signiﬁcant interactions between condition and genotype [F2,84¼ 3.166, p< 0.05], condition and treatment (i.e., with or
without dox) [F2,84¼ 9.717, p< 0.001], and among condition, treatment, and genotype [F2,84¼ 8.542, p< 0.001]. Bonferroni corrected pair-wise comparisons conﬁrmed that acute
cocaine exposure augmented locomotion (ps< 0.001) over that of baseline activity for WT and dtg mice, regardless of dox status. WT mice with or without dox treatment
demonstrated further increases in locomotion at challenge relative to activity levels at baseline (ps< 0.001) as well as upon ﬁrst exposure to cocaine (ps< 0.005). By comparison,
dtg mice without dox treatment failed to show increased locomotion at cocaine challenge relative to activity levels at ﬁrst exposure to cocaine; mutants given dox had marked
increases in locomotion relative to levels at baseline (p< 0.001) and upon acute cocaine exposure (p< 0.03), demonstrating that dox rescued behavioral sensitization in the dtg
animals. Notably, WT and dtg mice maintained on dox only differed in their behavioral responses to cocaine at the time of challenge at 28 days (p< 0.001). For the non-dox groups
N¼ 17 WT and 8 dtg mice, for dox-treated groups N¼ 8 WT and 6 dtg mice; *p< 0.05, WT versus dtg mice; þp< 0.05, within genotype comparison of acute or challenge versus
baseline activity; #p< 0.05, within genotype comparison of acute exposure versus challenge.
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the dnTrkB transgene in adulthood is required to prevent sensiti-
zation to an acute exposure to cocaine. Importantly, expression of
the transgene beginning in late embryonic development and per-
sisting through postnatal development alone is not sufﬁcient to
inhibit one-day cocaine sensitization in adulthood.3.7. Expression of dnTrkB prevents CPP
Most drugs of abuse have some reward potential (Johanson,
1978). To determine whether dnTrkB expression interfered with
the rewarding properties of cocaine in our single injection protocol,
WT and dtg mice were tested in CPP. This experiment was con-
ducted over 8 days and comprised 3 phases: pre-training (4 days)
where mice were acclimated to the conditioning/test apparatus,
training (2 days)where animals received single exposures to vehicle
and cocaine, a 1 day vehicle/cocaine-free hiatus, and a 1 day test
where CPP was assessed. The WT and dtg untreated mice (i.e., no
Dox condition) spent similar amounts of time in each of the two
conditioning chambers at pre-training (Fig. 6A, B, Left). An exami-
nation of the results at the time of testing revealed that theWTmice
developed CPP to cocaine (Fig. 6C, Left), whereas dtg animals failed
to display this behavior (Fig. 6D, Left).
To determine whether expression of the dnTrkB transgene was
responsible for eliminating CPP in dtg mice, additional groups of
naïve WT and dtg animals were raised in the absence of dox then
given dox in adulthood 14 days prior to CPP testing. Dox adminis-
tration to WT and dtg mice exerted no effects on the times spent in
the to be conditioned saline- and cocaine-paired chambers at pre-
training (Fig. 6A, B, Right). At the time of testing, dox did not
inﬂuence performance of WT animals, as they still demonstrated
CPP to cocaine (Fig. 6C, Right). In the absence of dnTrkB expression,
dtg mice now displayed CPP to cocaine (Fig. 6D, Right) to a similar
extent as WTcontrols (Fig. 6C, Right). Since at pre-test bothWT and
dtg mice spent some time in the chamber that would be paired
subsequently with cocaine, the proclivity to remain in this chamberat testing following the single pairing with cocaine was examined
in terms of percent change in time spent in this location. Regardless
of dox status, WT mice showed similar increases in the percent
time spent in this chamber from pre-training to testing following
the single cocaine exposure (Fig. 6E). By comparison, the dtg mice
without dox spent similar percent times in the cocaine-paired
chamber at pre-training and at testing; however, mutants given
dox showed increased percent time in the cocaine-paired chamber
at testing and this was comparable to that of theWTcontrols. These
ﬁndings were further conﬁrmed when the data were examined in
terms of preference scores (Fig. 6F). Together, these results
demonstrate that TrkB activation in adulthood is required for the
development of CPP to a single exposure to cocaine.
3.8. The dnTrkB transgene prevents cocaine-induced TrkB activation
The absence of behavioral sensitization and CPP to acute cocaine
exposure in dtg mice suggested that expression of the dnTrkB
transgene prevented the cocaine-induced enhancement of TrkB
activation. To address this question, WT and dtg mice were
euthanized 9 h after exposure to saline or 20 mg/kg cocaine (i.p.)
and levels of p-TrkB in the NAc were analyzed by immunoprecipi-
tation and Western blot. Administration of cocaine to WT mice
resulted in an approximate 3-fold increase in p-TrkB in the NAc
(Fig. 7, top). By contrast, no increase in p-TrkB immunoreactivity
was detected following cocaine administration to the dtg mice
(Fig. 7, bottom).
4. Discussion
Since local injection of BDNF into the NAc promotes behavioral
sensitization to cocaine (Horger et al., 1999) and because BDNF
infusions into this brain area enhance self-administration of
cocaine for at least for one month after BDNF administration has
terminated (Grimm et al., 2003; Horger et al., 1999), we have
hypothesized that a single cocaine injection may be sufﬁcient to
Fig. 6. Expression of the dnTrkB transgene prevents CPP to a single exposure to cocaine. (A,B) The data are presented as the time spent in the cocaine- and saline-paired chambers.
During pre-training, WT (A) and dtg (B) mice without or with dox spent similar amounts of time in the chambers to be paired subsequently with cocaine or saline. An omnibus
RMANOVA found no signiﬁcant within subjects effects of chamber pairings, genotype, or dox treatment, or interactions between/among these effects at pre-training. (C) At testing,
WT mice without (Left) or with dox (Right) demonstrate CPP by spending more time in the cocaine- compared to saline-paired chamber. (D) By comparison, dtg mice without dox
(Left) spent similar amounts to time in both chambers; dox-treated dtg mice (Right) spent more time in the cocaine-paired chamber. An omnibus RMANOVA found within subjects
effects of test chamber (saline or cocaine) [F1,37¼ 25.335, p< 0.001] and the test chamber by genotype [F1,37¼ 5.996, p< 0.019] and the test chamber by genotype by treatment
interactions [F1,37¼14.537, p< 0.001] to be signiﬁcant. Bonferroni corrected pair-wise comparisons revealed that WT mice spent more time in the cocaine- compared to the saline-
paired chamber, regardless of dox treatment status (ps< 0.040). WT mice without or with dox were not different from each other. By contrast, untreated dtg mice spent similar
amounts of time in both chambers; however, they spent more time in the cocaine-paired chamber when given dox (p< 0.001). Notably, the amount of time the dox-treated dtg
animals spent in this chamber was similar to that of WT controls. (E) The data are presented as the percent change in time spent in the cocaine-paired chamber from pre-training to
test. Although the percent time spent in the cocaine-paired chamber was increased and was not different between WT mice without or with dox, only dtg mice given dox showed
this same change. ANOVA noted main effects of treatment [F1,37¼ 7.882, p< 0.001] and the treatment by genotype interaction [F1,37¼10,825 p< 0.002] to be signiﬁcant. Bonferroni
analyses showed that regardless of dox status, WT mice had a greater than 35% increase in time spent in the cocaine-paired chamber at test compared to that at pre-training. By
contrast, dtg animals without dox at test failed to show any increase in the percent time spent in the cocaine-paired chamber compared to pre-training and this was signiﬁcantly
reduced below that of the WT controls (p< 0.001). Dox treatment in dtg animals markedly increased this percent time relative to the non-treated mutants (p< 0.001) and this was
not different from the WT mice without or with dox. (E) Preference scores represented as the time spent in the saline chamber subtracted from the time spent in the cocaine
chamber divided by the total time spent in both chambers. Only dtg mice without dox displayed no preference for the cocaine-paired chamber at testing. ANOVA observed
signiﬁcant main effects of genotype [F1,37¼ 12.586, p< 0.001] and treatment [F1,37¼ 3.746, p< 0.047], and a signiﬁcant genotype by treatment interaction [F1,37¼17.442, p< 0.001].
Bonferroni comparisons showed that preference for the cocaine-paired chamber among WT mice did not differ relative to dox status. By contrast, dtg mice without dox showed
reduced preference for the cocaine-paired chamber relative to WT controls (p< 0.001) and the mutants given dox (p< 0.001). The preference in these latter animals did not differ
from those of WT controls without or with dox. For the non-dox groups N¼ 13 WT and 12 dtg mice, for dox-treated groups N¼ 8 WT and 8 dtg mice; *p< 0.05, WT versus dtg mice
within dox treatment condition; þp< 0.05, no dox versus dox within genotype; ^p< 0.05, compared to the cocaine-paired chamber within genotype.
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Fig. 7. Expression of the dnTrkB transgene prevents cocaine-induced TrkB activation in
the NAc. Cocaine increases p-TrkB in the NAc in WT mice (top), but not in dtg mice
(bottom). N¼ 3 experiments.
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behavioral sensitization. To test this idea we have used a transgenic
mouse expressing a conditional dominant negative form of TrkB
(dnTrkB) and have assessed cocaine-induced biochemical and
behavioral responses in this mutant. Four principal ﬁndings have
emerged. First, a single exposure to cocaine is sufﬁcient to increase
TrkB activation within the NAc as evidenced by enhanced levels of
p-TrkB within the NAc 9e12 h after cocaine administration. Second,
selective expression of dnTrkB in adulthood prevents the locomotor
sensitizing effects of acute cocaine exposure. Third, expression of
the dnTrkB transgene blocks CPP to a single cocaine exposure.
Fourth, expression of the dnTrkB abrogates the cocaine-induced
increase in p-TrkB within the NAc. These ﬁndings demonstrate
that TrkB activation is required both for behavioral sensitization
and for enhanced CPP to a single exposure to cocaine.
Previous studies have demonstrated that perturbations in
BDNF/TrkB signaling can alter behavioral responses to cocaine
(Bahi et al., 2008; Graham et al., 2007, 2009; Grimm et al., 2003;
Hall et al., 2003; Horger et al., 1999; Pu et al., 2006). These ﬁnd-
ings raise the possibility that cocaine exposure may lead to
enhanced TrkB signaling which, in turn, may mediate some of the
molecular and cellular events that underlie the development of
addictive-like behaviors. In support of this idea, we ﬁnd that
a single exposure to cocaine is sufﬁcient to enhance levels of p-TrkB
e a surrogate measure of TrkB activation e within the NAc. This
increase is ﬁrst detected at 9 h and is still evident at 12 h, but it
returns to baseline within 24 h after cocaine administration.
Although we observed no changes in the levels of total TrkB protein
in murine NAc over the 24 h period, levels of total TrkB or the
downstream phospholipase C-g are reported to be increased in rat
NAc within 4h after the end of a session of cocaine self-
administration (Graham et al., 2007, 2009). While the discrepancy
between the experiments may be due to the species of rodent
tested and/or the route of administration, both ﬁndings indicate
that the BDNF-TrkB system in the NAc is highly responsive to
cocaine.
The fact that a single injection of cocaine is sufﬁcient to increase
endogenous levels of p-TrkB within the NAc strengthens the
possibility that TrkB activation may promote changes in neural
plasticity associated with this drug. Evaluating this idea in adult
mice with preexisting genetic modiﬁcations is potentially
confounded by the effects of TrkB signaling during neuronal
development. To address this point, we developed a dnTrkB mouse
where the transgene is expressed in restricted regions of the
forebrain in an inducible and repressible manner. Expression of
dnTrkB continuously from the late embryonic period throughout
life abolished the development of both behavioral sensitization and
CPP to a single exposure to cocaine. Nevertheless, expression of
dnTrkB during development alone was not sufﬁcient to mediate
these effects, because eliminating dnTrkB expression just prior to
and during the period of cocaine exposure in adulthood restored
the ability of the dtg mice to develop behavioral sensitization andCPP. Thus, expression of the dnTrkB transgene at the time of cocaine
exposure eliminates the development of sensitization and CPP to
a single injection of cocaine. In our studywewanted to evaluate the
initial biochemical changes to a single administration of cocaine
rather than the cumulative effects of multiple cocaine exposures on
various signaling pathways (c.f., Hope et al., 1994). Nonetheless, it
may be anticipated that dtg mice may eventually develop behav-
ioral sensitizationwith repeated cocaine dosing since this response
is delayed in BDNF heterozygous mice (Horger et al., 1999).
The question arises as to the anatomical location of cocaine-
induced TrkB activation required for the development of behavioral
sensitization and CPP.We found a detectable increase inp-TrkB in the
NAcbeginning9 hafter cocaine administration. This cocaine-induced
increase in TrkB activation, together with restriction of dnTrkB
expression to the forebrain and the relatively low expression of
dnTrkB outside the striatum in our transgenicmice, supports the idea
that TrkB activation within the NAc is critical for behavioral sensiti-
zation and CPP to a single cocaine injection. Indeed, this same brain
area has also been reported to be important for supporting these
same behaviors as well as self-administration when animals are
given repeated cocaine injections (Bahi et al., 2008; Graham et al.,
2009). Nevertheless, because in our own experiments the trans-
gene is expressed in forebrain areas (even at relatively low levels)
besides the NAc, a possibility exists that TrkB inactivation in these
additional areas may also play some role in the behavioral responses
of the dtg mice to acute cocaine administration.
The mechanism by which the dnTrkB transgene prevents
sensitization and CPP to a single cocaine exposure may involve
abrogation of TrkB activation, a presumption strengthened by
direct biochemical studies in the dnTrkB mice. Under normal
circumstances, activation of TrkB occurs through dimerization and
subsequent phosphorylation of eachmonomer by its dimer partner.
The phosphorylated state of both members of the homodimer is
thought to be required for the conformational change leading to the
binding and subsequent phosphorylation of interacting proteins
including shc, phosphoinositol 3-kinase, and phospholipase C-g
(see Reichardt, 2006). The dnTrkB transgene inhibits activation of
TrkB by forming inactive heterodimers (WT-TrkB:dnTrkB) or
homodimers (dnTrkB:dnTrkB). Although the dnTrkB monomer can
presumably serve as a substrate for its WT-TrkB partner, the
absence of the ATP binding site in the dnTrkB protein eliminates its
kinase function and precludes phosphorylation of its WT-TrkB
partner – the net effect being a functionally inactive heterodimer.
Elimination of BDNF-induced neurite outgrowth of dnTrkB-
transfected PC12 cells supports this idea. Likewise eliminating the
cocaine-induced increase of p-TrkB in the NAc is consistent with
this notion. The slight increase in p-TrkB levels in saline-treated
dnTrkB animals compared to saline-treated WT-TrkB mice
presumably reﬂects phosphorylation of dnTrkB members of inac-
tive heterodimers by the WT-TrkB partners.
The cellularandmolecular consequences bywhich enhancedTrkB
activation may contribute to these cocaine-mediated events are
uncertain. One possibility involves increased expression of the
dopamine D3 receptor. A selective D3 receptor antagonist blocks
the development and expression of cocaine CPP (Vorel et al., 2002).
Interestingly, D3 and TrkB receptormRNAs are largely co-localized in
neurons within the NAc and BDNF promotes increased expression of
D3 receptor mRNA within this brain area as evident by studies of
BDNF heterozygous mice and by infusions of BDNF directly into the
NAc (Guillin et al., 2001). A single exposure to cocaine is sufﬁcient to
induce increased D3 receptor mRNA and binding in the NAc and
increased BDNF mRNA contents in frontal and medial prefrontal
cortexwithin2e3 h (Le Foll et al., 2005). Together theseﬁndings raise
the possibility that acute cocaine administration induces increased
expression of BDNF mRNA in these neocortical areas where it is
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to be released to activate TrkB. Alternatively, the recent discovery of
BDNF mRNA intrinsic to the NAc (Filip et al., 2006; Liu et al., 2006)
raises the possibility that increased transcription and translation of
BDNF locally within the NAc might underlie the cocaine-induced
enhanced activation of TrkB. In this regard, phospholipase C-g,
a downstream target of TrkB activation, has been reported to be
phosphorylated in response to cocaine self-administation (Graham
et al., 2007). Additionally, enhanced activation of TrkB on dopamine
axon terminals within the NAcmay promote increased release of this
monoamine (see Seroogy et al., 1994); thereby contributing to the
cocaine-induced behavioral changes (Grimm et al., 2003; Guillin
et al., 2001; Horger et al., 1999). Apart from these potential molec-
ular consequences, increased TrkB signaling has been linked to
dendritic changes in a variety of preparations (Danzer et al., 2002;
Horch and Katz, 2002; Yacoubian and Lo, 2000) that are similar to
those described on medium spiny neurons within the NAc in asso-
ciation with changes induced by sensitization to psychostimulants
(Robinson and Kolb, 1997, 1999).
In summary, our data demonstrate that although expression of
the dnTrkB transgene at the time of acute cocaine exposure exerts
no effects on the initial cocaine-induced response, it abolishes the
acute cocaine-induced activation of TrkB in the NAc and prevents
the development of behavioral sensitization and CPP in dtg mice.
Together our ﬁndings demonstrate that TrkB activation plays an
essential, not merely regulatory, role in these single-injection
animal models of addiction, and they focus the search for mecha-
nisms on the structural and functional consequences of TrkB
activation. Our rsults suggest that TrkB and its downstream
signaling pathways may be attractive molecular targets for thera-
pies aimed at preventing addiction.Acknowledgements
This work was supported by NIH grants NS17771 and NS056217
(J.O.M.) and Unrestricted Funds (W.C.W.).Appendix. Supplementary information
Supplementary data associated with this article can be found in
the online version at doi:10.1016/j.neuropharm.2010.01.014.References
Altar, C.A., Cai, N., Bliven, T., Juhasz, M., Conner, J.M., Acheson, A.L., Lindsay, R.M.,
Wiegand, S.J., 1997. Anterograde transport of brain-derived neurotrophic factor
and its role in the brain. Nature 389, 856e860.
Bahi, A., Boyer, F., Chandrasekar, V., Dreyer, J.-L., 2008. Role of accumbens BDNF and
TrkB in cocaine-induced psychomotor sensitization, conditioned-place prefer-
ence, and reinstatement in rats. Psychopharmacology (Berl.) 199, 169e182.
Berglind, W.J., See, R.E., Fuchs, R.A., Ghee, S.M., Whitﬁeld Jr., T.W., Miller, S.W.,
McGinty, J.F., 2007. A BDNF infusion into the medial prefrontal cortex
suppresses cocaine seeking in rats. Eur. J. Neurosci. 26, 757e766.
Berton, O., McClung, C.A., Dileone, R.J., Krishnan, V., Renthal, W., Russo, S.J.,
Graham, D., Tsankova, N.M., Bolanos, C.A., Rios, M., Monteggia, L.M., Self, D.W.,
Nestler, E.J., 2006. Essential role of BDNF in the mesolimbic dopamine pathway
in social defeat stress. Science 311, 864e868.
Black, I.B., Lessmann, V., 1999. Trophic regulation of synaptic plasticity:
neurotrophin-dependent modulation of glutamatergic synaptic transmission in
the mammalian CNS. J. Neurobiol. 41, 108e118.
Bramham, C.R., Messaoudi, E., 2005. BDNF function in adult synaptic plasticity: the
synaptic consolidation hypothesis. Progr. Neurobiol. 76, 99e125.
Burgin, K.E., Waxham, M.N., Rickling, S., Westgate, S.A., Mobley, W.C., Kelly, P.T.,
1990. In situ hybridization histochemistry of Ca2þ/calmodulin-dependent
protein kinase in developing rat brain. J. Neurosci. 10, 1788e1798.
Butovsky, E., Juknat, A., Goncharov, I., Elbaz, J., Eilam, R., Zangen, A., Vogel, Z., 2005.
In vivo up-regulation of brain-derived neurotrophic factor in speciﬁc brain areas
by chronic exposure to delta-tetrahydrocannabinol. J. Neurochem. 93, 802e811.
Danzer, S.C., Crooks, K.R., Lo, D.C., McNamara, J.O., 2002. Increased expression of
brain-derived neurotrophic factor induces formation of basal dendrites andaxonal branching in dentate granule cells in hippocampal explant cultures.
J. Neurosci. 22, 9754e9763.
Filip, M., Faron-Gorecka, A., Kusmider, M., Golda, A., Frankowska, M., Dziedzicka-
Wasylewska, M., 2006. Alterations in BDNF and trkB mRNAs following acute or
sensitizing cocaine treatments and withdrawal. Brain Res. 1071, 218e225.
Gossen, M., Bujard, H., 1992. Tight control of gene expression in mammalian cells by
tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A. 89, 5547e5551.
Graham, D.L., Edwards, S., Bachtell, R.K., DiLeone, R.J., Rios, M., Self, D.W., 2007.
Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-
administration and relapse. Nat. Neurosci. 10, 1029e1037.
Graham, D.L., Krishnan, V., Larson, E.B., Graham, A., Edwards, S., Bachtell, R.K.,
Simmons, D., Gent, L.M., Berton, O., Bolanos, C.A., DiLeone, R.J., Parada, L.F.,
Nestler, E.J., Self, D.W., 2009. Tropomycin-related kinase B in the mesolimbic
dopamine system: region-speciﬁc effects on cocaine reward. Biol. Psychiatry 65,
696e701.
Grignaschi, G., Burbassi, S., Zennaro, E., Bendotti, C., Cervo, L., 2004. A single high
dose of cocaine induces behavioural sensitization and modiﬁes mRNA encoding
GluR1 and GAP-43 in rats. Eur. J. Neurosci. 20, 2833e2837.
Grimm, J.W., Lu, L., Hayashi, T., Hope, B.T., Su, T.-P., Shaham, Y., 2003. Time-
dependent increases in brain-derived neurotrophic factor protein levels within
the mesolimbic dopamine system after withdrawal from cocaine: implications
for incubation of cocaine craving. J. Neurosci. 23, 742e747.
Guillin, O., Diaz, J., Carroll, P., Griffon, N., Schwartz, J.C., Sokoloff, P., 2001. BDNF
controls dopamine D3 receptor expression and triggers behavioural sensitiza-
tion. Nature 411, 86e89.
Hall, F.S., Drgonova, J., Goeb, M., Uhl, G.R., 2003. Reduced behavioral effects of
cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout
mice. Neuropsychopharmacology 28, 1485e1490.
Hanson, P.I., Schulman, H., 1992. Neuronal Ca2þ/calmodulin-dependent protein
kinases. Annu. Rev. Biochem. 61, 559e601.
He, X.P., Kotloski, R., Nef, S., Luikart, B.W., Parada, L.F., McNamara, J.O., 2004.
Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the
kindling model. Neuron 43, 31e42.
Hope, B.T., Nye, H.E., Kelz, M.B., Self, D.W., Iadarola, M.J., Nakabeppu, Y., Duman, R.S.,
Nestler, E.J., 1994. Induction of a long-lasting AP-1 complex composed of altered
Fos-like proteins in brain by chronic cocaine and other chronic treatments.
Neuron 13, 1235e1244.
Horch, H.W., Katz, L.C., 2002. BDNF release from single cells elicits local dendritic
growth in nearby neurons. Nat. Neurosci. 5, 1177e1184.
Horger, B.A., Iyasere, C.A., Berhow, M.T., Messer, C.J., Nestler, E.J., Taylor, J.R., 1999.
Enhancement of locomotor activity and conditioned reward to cocaine by
brain-derived neurotrophic factor. J. Neurosci. 19, 4110e4122.
Johanson, C.E., 1978. Drugs as reinforcers. In: Blackman, D.E., Sanger, D.J. (Eds.),
Contemporary Research in Behavioral Pharmacology. Plenum Press, New York,
pp. 325e390.
Kalb, R., 2005. The protean actions of neurotrophins and their receptors on the life
and death of neurons. Trends Neurosci. 28, 5e11.
Kalivas, P.W., Alesdatter, J.E., 1993. Involvement of N-methyl-D-aspartate receptor
stimulation in the ventral tegmental area and amygdala in behavioral sensiti-
zation to cocaine. J. Pharmacol. Exp. Ther. 267, 486e495.
Klein, R., Smeyne, R.J., Wurst, W., Long, L.K., Auerbach, B.A., Joyner, A.L.,
Barbacid, M., 1993. Targeted disruption of the trkB neurotrophin receptor gene
results in nervous system lesions and neonatal death. Cell 75, 113e122.
Krestel, H.E., Mayford, M., Seeburg, P.H., Sprengel, R., 2001. A GFP-equipped bidi-
rectional expression module well suited for monitoring tetracycline-regulated
gene expression in mouse. Nucleic Acids Res. 29, E39.
Le Foll, B.C.A., Diaz, J., Sokoloff, P., 2005. A single cocaine exposure increases BDNF
and D3 receptor expression: implications for drug-conditioning. Neuroreport
16, 175e178.
Lessmann, V., 1998. Neurotrophin-dependent modulation of glutamatergic synaptic
transmission in the mammalian CNS. Gen. Pharmacol. 31, 667e674.
Liu, Q.R., Lu, L., Zhu, X.G., Gong, J.P., Shaham, Y., Uhl, G.R., 2006. Rodent BDNF genes,
novel promoters, novel splice variants, and regulation by cocaine. Brain Res.
1067, 1e12.
Lu, L., Dempsey, J., Liu, S.Y., Bossert, J.M., Shaham, Y., 2004. A single infusion of brain-
derived neurotrophic factor into the ventral tegmental area induces long-lasting
potentiation of cocaine seeking after withdrawal. J. Neurosci. 24, 1604e1611.
Luikart, B.W., Nef, S., Virmani, T., Lush, M.E., Liu, Y., Kavalali, E.T., Parada, L.F., 2005.
TrkB has a cell-autonomous role in the establishment of hippocampal Schaffer
collateral synapses. J. Neurosci. 25, 3774e3786.
Mayford, M., Bach, M.E., Huang, Y.-Y., Wang, L., Hawkins, R.D., Kandel, E.R., 1996.
Control of memory formation through regulated expression of a CaMKII
transgene. Science 274, 1678e1683.
McGough, N.N., He, D.Y., Logrip, M.L., Jeanblanc, J., Phamluong, K., Luong, K.,
Kharazia, V., Janak, P.H., Ron, D., 2004. RACK1 and brain-derived neurotrophic
factor: a homeostatic pathway that regulates alcohol addiction. J. Neurosci. 24,
10542e10552.
Miller, S.G., Kennedy, M.B., 1986. Regulation of brain type II Ca2þ/calmodulin-
dependent protein kinase by autophosphorylation: a Ca2þ-triggered molecular
switch. Cell 44, 861e870.
Nibuya, M., Morinobu, S., Duman, R.S., 1995. Regulation of BDNF and trkB mRNA in
rat brain by chronic electroconvulsive seizure and antidepressant drug treat-
ments. J. Neurosci. 15, 7539e7547.
Pierce, R.C., Bari, A.A., 2001. The role of neurotrophic factors in psychostimulant-
induced behavioral and neuronal plasticity. Rev. Neurosci. 12, 95e110.
K.R. Crooks et al. / Neuropharmacology 58 (2010) 1067e1077 1077Pogorelov, V.M., Rodriguiz, R.M., Insco, M.L., Caron, M.G., Wetsel, W.C., 2005.
Novelty seeking and stereotypic activation of behavior in mice with disruption
of the Dat1 gene. Neuropsychopharmacology 30, 1818e1831.
Pu, L., Liu, Q.S., Poo, M-m, 2006. BDNF-dependent synaptic sensitization in midbrain
dopamine neurons after cocaine withdrawal. Nat. Neurosci. 9, 605e607.
Reichardt, L.F., 2006. Neurotropin-regulated signaling pathways. Phil. Trans. R. Soc.
B 361, 1545e1564.
Robinson, T.E., Berridge, K.C., 2001. Incentive-sensitization and addiction. Addiction
96, 103e114.
Robinson, T.E., Kolb, B., 1997. Persistent structural modiﬁcations in nucleus
accumbens and prefrontal cortex neurons produced by previous experience
with amphetamine. J. Neurosci. 17, 8491e8497.
Robinson, T.E., Kolb, B., 1999. Alterations in the morphology of dendrites and
dendritic spines in the nucleus accumbens and prefrontal cortex following
repeated treatment with amphetamine or cocaine. Eur. J. Neurosci. 11,
1598e1604.
Rodriguiz, R.M., Wetsel, W.C., 2006. Assessments of cognitive deﬁcits in mutant
mice. In: Levin, E.B., Buccafusco, J.J. (Eds.), Animal Models of Cognitive
Impairment. CRC Press, Boca Raton, FL, pp. 223e284.
Rodriguiz, R.M., Gadnidze, K., Ragnauth, A., Dorr, N., Yanagisawa, M., Wetsel, W.C.,
Devi, L.A., 2008. Animals lacking endothelin converting enzyme-2 are deﬁcient
in learning and memory. Genes Brain Behav. 7, 418e426.
Russo, S.J., Mazei-Robison, M.S., Ables, J.L., Nestler, E.J., 2009. Neurotrophic factors
and structural plasticity in addiction. Neuropharmacology 56, 73e82.Seroogy, K.B., Lundgren, K.H., Tran, T.M., Guthrie, K.M., Isackson, P.J., Gall, C.M., 1994.
Dopaminergic neurons in rat ventral midbrain express brain-derived neuro-
trophic factor and neurotrophin-3 mRNAs. J. Comp. Neurol. 342, 321e334.
Siuciak, J.A., Lewis, D.R., Wiegand, S.J., Lindsay, R.M., 1997. Antidepressant-like effect
of brain-derived neurotrophic factor (BDNF). Pharmacol. Biochem. Behav. 56,
131e137.
Vanderschuren, L.J., Schmidt, E.D., De Vries, T.J., Van Moorsel, C.A., Tilders, F.J.,
Schoffelmeer, A.N., 1999. A single exposure to amphetamine is sufﬁcient to
induce long-term behavioral, neuroendocrine, and neurochemical sensitization
in rats. J. Neurosci. 19, 9579e9586.
Vorel, S.R., Ashby Jr., C.R., Paul, M., Liu, X., Hayes, R., Hagan, J.J., Middlemiss, D.N.,
Stemp, G., Gardner, E.L., 2002. Dopamine D3 receptor antagonism inhibits
cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 22,
9595e9603.
Xu, B., Goulding, E.H., Zang, K., Cepoi, D., Cone, R.D., Jones, K.R., Tecott, L.H.,
Reichardt, L.F., 2003. Brain-derived neurotrophic factor regulates energy
balance downstream of melanocortin-4 receptor. Nat. Neurosci. 6, 736e742.
Yacoubian, T.A., Lo, D.C., 2000. Truncated and full-length TrkB receptors regulate
distinct modes of dendritic growth. Nat. Neurosci. 3, 342e349.
Yamamoto, A., Lucas, J.J., Hen, R., 2000. Reversal of neuropathology and motor
dysfunction in a conditional model of Huntington's disease. Cell 101, 57e66.
Zhang, D., Zhang, L., Lou, D.W., Nakabeppu, Y., Zhang, J., Xu, M., 2002. The
dopamine D1 receptor is a critical mediator for cocaine-induced gene
expression. J. Neurochem. 82, 1453e1464.
